PHLORIZIN
September 21, 2021GLUCONEOGENESIS
September 21, 2021- Inhibition of Renal Glucose Reabsorption: a novel strategy for achieving Glucose control in type 2 diabetes mellitus
- Inhibition of Renal Glucose Reabsorption as a novel treatment for diabetes patients
- Renal Glucose Reabsorption inhibitors to treat diabetes
- Characterization of Renal Glucose Reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
- Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in Renal Glucose Reabsorption in humans
- Development of the Renal Glucose Reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2
- Effect of Lepidium sativum L. on Renal Glucose Reabsorption and urinary TGF‐β1 levels in diabetic rats
- Selective SGLT2 Inhibition by tofogliflozin reduces Renal Glucose Reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
- Antihyperglycemic effect of T-1095 via Inhibition of Renal Na+-Glucose cotransporters in streptozotocin-induced diabetic rats
- Renal Glucose transporters: novel targets for hyperglycemia management
- Role of the kidney in normal Glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- Renal, metabolic and cardiovascular considerations of SGLT2 Inhibition
- Sodium-Glucose cotransporter-2 Inhibition and the glomerulus: a review
- From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
- Type 2 sodium-Glucose cotransporter (SGLT2) inhibitors: from familial Renal glucosuria to the treatment of type 2 diabetes mellitus
- Inhibition of the intestinal sodium‐coupled Glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood Glucose levels in mice …
- Glucose metabolism in the kidney: neurohormonal activation and heart failure development
- The role of the kidney and sodium-Glucose cotransporter-2 Inhibition in diabetes management
- Effect of phlorhizin on Renal Glucose and phosphate transport in the dog
- Exploring newer target sodium Glucose transporter 2 for the treatment of diabetes mellitus
- Glucose control by the kidney: an emerging target in diabetes
- Targeting Renal Glucose Reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
- Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
- Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors
- Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes
- Dapagliflozin: a sodium Glucose cotransporter 2 inhibitor in development for type 2 diabetes
- SGLT2 Inhibition in diabetes mellitus: rationale and clinical prospects
- Effect of sodium-Glucose cotransport Inhibition on polycystic kidney disease progression in PCK rats
- Sodium Glucose co-transporter 2 (SGLT2) inhibitor
- Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary Glucose excretion in healthy subjects
- The role of the kidneys in Glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium Glucose co-transporter 2 …
- SGLT2 Inhibition—a novel strategy for diabetes treatment
- Tofogliflozin, a potent and highly specific sodium/Glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
- SGLT2 inhibitors: molecular design and potential differences in effect
- Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice
- Sodium‐Glucose co‐transporter (SGLT) and Glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
- Does urea Reabsorption occur via the Glucose pathway in the kidney of the freshwater rainbow trout?
- Model analysis of effect of canagliflozin (Invokana), a sodium–Glucose cotransporter 2 inhibitor, to alter plasma 1, 5-anhydroglucitol
- Modified cycloartanes with improved inhibitory effect on SGLT-mediated Glucose uptake in human Renal proximal tubular cells
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats
- Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
- Hypoglycaemic activity of Retama raetam in rats
- Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-Glucose co-transporter type 2
- Role of the kidney in Glucose homeostasis: implications for SGLT-2 Inhibition in the treatment of type 2 diabetes mellitus
- Sodium-Glucose co-transport inhibitors
- Dapagliflozin: a selective sodium-Glucose co-transporter-2 inhibitor in type 2 diabetes.
- In vitro–in vivo correlation of the Inhibition potency of sodium-Glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach
- Siphoning Blood Glucose: A Novel Therapy
- T-1095, a Renal Na+-Glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
- The role of the kidneys in Glucose homeostasis: a new path towards normalizing glycaemia
- Dapagliflozin, a selective SGLT2 inhibitor, improves Glucose homeostasis in normal and diabetic rats
- Sodium Glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes
- Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent Glucose co-transporter 2, in …
- Targeting the kidney and Glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 Inhibition as a new option for treatment of type 2 …
- Lowering plasma Glucose concentration by inhibiting Renal sodium–Glucose cotransport
- Development of the sodium-Glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus
- Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent Glucose transporter 2 inhibitor …
- Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected Renal effects
- The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta‐analysis
- Associations of insulin levels and insulin resistance with urine Glucose excretion independent of blood Glucose in Chinese adults with prediabetes and newly …
- Unmasking and aggravation of polycythemia vera by canagliflozin
- Effects of Kaempferia parviflora Extract on Glucose Transporters in Human Renal Proximal Tubular Cells
- Renal sodium-Glucose cotransporter Inhibition in the management of type 2 diabetes mellitus
- Meet the SGLT2 inhibitors: these new type 2 diabetes medications block Glucose Reabsorption by the kidneys
- Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
- Sodium-Glucose co-transporters and their Inhibition: clinical physiology
- The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-Glucose co-transporter 2 (SGLT-2)
- Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
- SODIUM-Glucose TRANSPORTER 2 Inhibition–A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
- SGLT2 inhibitors for type 2 diabetes
- Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases
- SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
- Antidiabetic drugs and the kidney
- Differentiating sodium-Glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
- Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model
- Tofogliflozin: the road goes ever on
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- Distribution of Glucose transporters in Renal diseases
- New potent antihyperglycemic agents in db/db mice: Synthesis and structure− activity relationship studies of (4-substituted benzyl)(trifluoromethyl) pyrazoles and …
- The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
- Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
- Dapagliflozin attenuates Renal gluconeogenic enzyme expression in obese rats
- Sodium–Glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
- A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy …
- Sodium Glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
- A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
- Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, for the management of type 2 diabetes
- Empagliflozin, a sodium Glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
- Mechanistic evaluation of the effect of sodium‐dependent Glucose transporter 2 inhibitors on delayed Glucose absorption in patients with type 2 diabetes mellitus …
- The Role of the Kidney in Glucose Homeostasis
- Natural products as lead compounds for sodium Glucose cotransporter (SGLT) inhibitors
- Role of sodium-Glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
- The Kidneys in Type 2 Diabetes Disturbed Glucose Homeostasis to Mechanism-Based Therapy
- Sodium-Glucose cotransporter 2 Inhibition in type 1 diabetes: simultaneous Glucose lowering and Renal protection?
- Kidney in diabetes: from organ damage target to therapeutic target
- The Renal effects of SGLT2 inhibitors and a mini-review of the literature
- Preventive effects of flavonoids on alloxan-induced diabetes mellitus in rats
- Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–Glucose co‐transporter type 2, in Japanese subjects without and with …
- Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐Glucose co‐transporter‐2, in people with type 2 diabetes mellitus
- Potent sodium/Glucose cotransporter SGLT1/2 dual Inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in …
- DAPA-HF trial: dapagliflozin evolves from a Glucose-lowering agent to a therapy for heart failure
- Dapagliflozin: A new drug for treatment of type 2 diabetes mellitus
- Dapagliflozin for the treatment of type 2 diabetes
- Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐Glucose cotransporter inhibitor T‐1095
- The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
- Sodium-Glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?
- p63 and SOX2 dictate Glucose reliance and metabolic vulnerabilities in squamous cell carcinomas
- Role of sodium/Glucose cotransporter Inhibition on a rat model of angiotensin II–dependent kidney damage
- Dapagliflozin: a review on efficacy, clinical effectiveness and safety
- Increased waist-to-hip ratio is associated with decreased urine Glucose excretion in adults with no history of diabetes
- EMPA-REG OUTCOME: the nephrologist’s point of view
- SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
- Effect of Renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes …
- Structure-activity relationships of preventive effects of flavonoids in alloxan-induced diabetes mellitus in rats
- Acute diuretic effect of aqueous extract of Retama raetam in normal rats
- Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
- Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent Glucose cotransporter 2 and clinical candidate for the …
- Impact of sodium–Glucose cotransporter 2 inhibitors on blood pressure
- Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes
- Effect of sodium‐Glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- SGLT2 inhibitors in patients with type 2 diabetes and Renal disease: overview of current evidence
- Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
- Sodium-Glucose Transporter 2 Inhibitors and Kidney
- Use of Sodium–Glucose Cotransporter 2 (SGLT-2) Inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
- Ertugliflozin as a monotherapy for the treatment of type 2 diabetes
- Pharmacogenetics of novel Glucose-lowering drugs
- Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate Renal impairment
- Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
- Short commentary on empagliflozin and its potential clinical impact
- Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats
- The novel role of the kidney in diabetes management: Sodium-Glucose Co-Transporter 2 Inhibitors
- Study of the hypoglycaemic activity of Lepidium sativum L. aqueous extract in normal and diabetic rats
- Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-Glucose transporters (SGLTs) in mice
- Long-term study of patients with type 2 diabetes and moderate Renal impairment shows that dapagliflozin reduces weight and blood pressure but does not …
- Evolution of sodium Glucose co-transporter 2 inhibitors as anti-diabetic agents
- Use of a sodium–Glucose cotransporter 2 inhibitor in a patient with chronic kidney disease
- Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’
- Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
- Identification of phlorizin binding domains in sodium-Glucose cotransporter family: SGLT1 as a unique model system
- Role of genetic variation in the human sodium–Glucose cotransporter 2 gene (SGLT2) in Glucose homeostasis
- Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
- The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
- Biopharmacological studies of the aqueous extract of Lepidium sativum seeds in alloxan-induced diabetes in rats
- The sodium Glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores Glucose homeostasis in the male zucker diabetic fatty rat
- Renal and cardiac implications of sodium Glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
- Improved Glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of …
- SGLT2i: A novel approach to managing type 2 diabetes
- Renal effects of sodium–Glucose cotransporter-2 inhibitors in patients with type 2 diabetes and Renal impairment
- Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review
- Patient considerations in the management of type 2 diabetes–critical appraisal of dapagliflozin
- Clinical relevance of the selectivity of sodium-Glucose cotransporter-2 inhibitors.
- Ipragliflozin, a sodium–Glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
- A Review on Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus
- Protection of the kidney with sodium–Glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
- Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, reduces post-meal Glucose excursion in patients with type 2 diabetes by a non-Renal mechanism …
- SGLT Inhibition: a possible adjunctive treatment for type 1 diabetes
- Sodium-Glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus
- Update review of the safety of sodium-Glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
- Sodium-coupled Glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
- Preclinical Species and Human Disposition of (1S, 2S, 3S, 4R, 5S)-5-[4-Chloro-3-(4-ethoxybenzyl) phenyl]-1-hydroxymethyl-6, 8-dioxabicyclo [3.2. 1] octane-2 …
- Regulation of Renal brush-border Glucose transport in response to metabolic dysregulation
- Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) Inhibition
- Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
- Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
- Sodium-Glucose cotransporter 2 inhibitors: the pleiotropic mechanisms of actions
- Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis
- An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
- Type 2 diabetes: An updated overview
- SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose
- Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
- SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
- Sugar absorption
- Role of the kidney and SGLT-2 Inhibition in type 2 diabetes mellitus
- SGLT2 inhibitors: not just another Glucose-lowering agent
- Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
- The use of sodium-Glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations
- Hypoglycemic activity of methanolic extract of Tectona grandis linn. Root in alloxan induced diabetic rats
- Effect of the desert plant Retama raetam on glycaemia in normal and streptozotocin-induced diabetic rats
- Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium Glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus
- Metformin supports the antidiabetic effect of a sodium Glucose cotransporter 2 inhibitor by suppressing endogenous Glucose production in diabetic mice
- SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
- High urinary Glucose is associated with improved Renal prognosis in patients with diabetes mellitus
- Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized …
- SGLT2 inhibitors–a potential treatment for Alport syndrome
- Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage …
- Development of sodium-dependent Glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics
- Lepidium species as antidiabetic herbal medicines
- Pathophysiology of Type 2 Diabetes
- The effect of saffron (Crocus sativus L.) and its ingredients on the management of diabetes mellitus and dislipidemia
- Luseogliflozin: first global approval
- A mechanistic investigation into the acute effects of apple polyphenols on carbohydrate digestion and absorption
- The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
- The potential role of sodium Glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
- Glucose lowering efficacy and pleiotropic effects of sodium-Glucose cotransporter 2 inhibitors
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
- Diabetes Mellitus, Obesity and Phytotherapy
- Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
- Ethnobotanical Survey of Medicinal Plants Used by Traditional Healers to Treat Diabetes in the Taza Region of Morocco
- The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
- Initial experience of SGLT2 inhibitor use in type 2 diabetes
- Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes
- Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the Renal …
- Pharmacologic management of type 2 diabetes mellitus: available therapies
- Hypoglycaemic effect of Triticum repens P. Beauv. in normal and diabetic rats
- Effects of diuretics on sodium-dependent Glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
- Mechanism and efficacy of new anti-diabetic medications
- Cardiovascular effects of sodium Glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
- Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes …
- Inhibitors of sodium-Glucose linked transporter 2-A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2
- Antinociceptive activity of aqueous extract of Lepidium sativum L. in mice
- Combination therapy for type 2 diabetes: dapagliflozin plus metformin
- A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant …
- Use of canagliflozin in combination with and compared to incretin-based therapies in type 2 diabetes
- Comparisons of weight changes between sodium‐Glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes …
- Diabetes and medicinal plants-A review
- Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats
- Role of insulin in the abnormal glucagon secretory response to hypoglycemia in type 1 diabetes
- The new direction in medical
- Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
- Novel avenues for treating diabetic nephropathy: new investigational drugs
- Effects of phlorizin on vascular complications in diabetes db/db mice
- A review: antidiabetic medicinal plants used for diabetes mellitus
- Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial Glucose concentrations following a high-carbohydrate meal: a randomized …
- Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
- ANTI-HYPERGLYCAEMIC EFFECT OF SOME UNANI FORMULATIONS IN THE MANAGEMENT OF DIABETES MELLITUS TYPE 2
- Drug off-target effects predicted using structural analysis in the context of a metabolic network model
- Effects of Zanthoxylum zanthoxyloides leaves on blood Glucose, lipid profile and some liver enzymes in alloxan induced diabetic rats
- Early administration of empagliflozin preserved heart function in cardioRenal syndrome in rat
- The sodium Glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
- Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
- Efficacy and safety of sodium‐Glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
- Energy loss via urine and faeces–a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight
- Sodium Glucose co-transporter-2 inhibitor: benefits beyond glycemic control
- Ketone bodies for kidney injury and disease
- Repurposing drugs to target the diabetes epidemic
- A systematic Review on Antidiabetic medicinal Plants
- Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight …
- The new direction in medical management of chronic heart failure with reduced ejection fraction
- Role of nutrient transporters in lifestyle-related diseases
- SGLT-2 inhibitors-hope or hype?-an updated review
- Biology of human sodium Glucose transporters
- Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
- New-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
- The role of glucagon in the acute therapeutic effects of SGLT2 Inhibition
- New pharmacological approaches to diabetes management
- Diuretic activity of methanolic extract of Physalis minima leaves
- New therapeutic strategies for type 2 diabetes CME
- Dandelion: Phytochemistry and clinical potential
- The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes
- Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
- Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
- Glucose lowering treatment modalities of type 2 diabetes mellitus
- www. OpenCME. org/course/where-do-sglt2-inhibitors-fit-spectrum-of-treatment-of-t2dm
- A systematic review on effect of canagliflozin in special population
- Selected biologically active substances and healing properties of dandelion (Taraxacum officinale)
- Hypoglycaemic activity and nephro-protectective effect of Bauhinia rufescens in alloxan-induced diabetic rats
- Lipid Accumulation Product Combined With Urine Glucose Excretion Improves the Efficiency of Diabetes Screening in Chinese Adults
- The Role of Adipose Tissue in Diabetic Kidney Disease
- Antihyperglycemic Studies on the Leaf Extract and Active Fractions of Newbouldia laevis (Bignoniaceae)
- Challenges for the treatment of diabetes mellitus
- Plants having potential antidiabetic activity: a review
- Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A Case Report
- Treatment approach to type 2 diabetes: Past, present and future
- OP8-3: Adaptive changes of transposed ileum and their potential roles in the metabolic benefits of bariatric surgery
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- The effect of dapagliflozin on clinical, metabolic and Renal parameters in type 2 diabetic patient in University of Malaya Medical Centre: A single centre experience/Ho …
- Antidiabetics Review on Natural Products
- An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations
- Potential role of yoga in management of the ominous octet: Adding a new facet to type 2 diabetes management and prevention
- Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote Glucose disposal and inflammation
- Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: A double-blinded …
- The metabolic model of heart failure: the role of sodium Glucose co-transporter-2 (SGLT-2) Inhibition
- Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload
- Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
- Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
- Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability
- Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in …
- PE-4: Effects of polydextrose on glycemic and insulinemic responses in healthy normal weight and overweight women when consumed during a breakfast meal
- Assessing the kidney function parameters glomerular filtration rate and effective Renal plasma flow with dynamic FDG-PET/MRI in healthy subjects
- Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
- The therapeutic journey of benzimidazoles: a review
- Sodium-Glucose cotransporter 2 inhibitors and cardiovascular outcomes
- Glucose transport at the Renal brush border membrane: GLUT2 and the involvement of PKC-βI
- Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
- Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
- Our Practice
- Asian Journal of Phytomedicine and Clinical Research
- Identification of key nodes of type 2 diabetes mellitus protein interactome and study of their interactions with phloridzin
- Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
- Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
- Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study
- Novel therapeutic agents for the treatment of diabetic kidney disease
- Pharmacognosy, phytochemistry, pharmacology and clinical applications of Taraxacum officinale
- The Future of Diabetes Therapy
- Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin: Original article: Roden M, Weng J …
- Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects
- Anti-ulcerogenic effects and anti-oxidative properties of Ceiba pentandra leaves on alloxan-induced diabetic rats
- A new analytical method for determination of dolutegravir and rilpivirine in pharmaceutical formulations by RP-HPLC method
- Arterial pressure lability is improved by sodium-Glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
- Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin–induced diabetic albino …
- Our Practice Newsletter: By Pharmacists For Pharmacists, issue 3
- Diabetes mellitus and use of medicinal plants for its treatment
- Present and future challenges in Type 2 diabetes
- Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
- Antidiabetic attributes of desert and steppic plants: a review
- Diabetes mellitus and hypertension: a dual threat
- Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice
- Therapeutic role of fibroblast growth factor 21 (FGF21) in the amelioration of chronic diseases
- Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET …
- Drug utilization patterns in patients with diabetes initiating sodium Glucose co-transporter-2 inhibitors (SGLT2i) in Japan: a multi-database study (2014–2017)
- Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study
- Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-Glucose cotransporter SGLT1 with high affinity
- Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study
- Some selected medicinal plants with antidiabetic potentials
- Pharmacologic treatment options for type 1 diabetes: what’s new?
- Contribution to the study of medicinal plants used in the treatment of diabetes, obesity and hypertension in Tafilalet region (Morocco)
- The physiological effects of dandelion (Taraxacum officinale) in type 2 diabetes
- Diabetes and cardiovascular risk in Renal transplant patients
- Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
- Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials
- OP8-2: The effect of bariatric surgery on fatty acid uptake and associated gene expression in abdominal subcutaneous adipose tissue of morbidly obese women
- Repurposing existing drugs for COVID-19: an endocrinology perspective
- SGLT-2 Inhibition in the kidney: changing paradigms in the treatment of type 2 diabetes mellitus
- Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
- Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose …
- Approach to diabetes management in patients with CVD
- Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
- Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
- The Ameliorative Potential of Saffron Against the Histological and Immunohistochemical Changes in Kidney of Albino Mice Due to Streptozotocin-Induced Diabetes …
- Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
- PE-1: Comparing the efficacy of different health education tools for improving blood Glucose control in patients with type 2 diabetes
- PE-2: Assessment of universal healthcare coverage of diabetes prevalence in a north India district: a rapid survey in urban and rural areas
- Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/Glucose‐cotransporter 2 …
- Hypoglycaemic and Hypolipidemic Effects of Black Brand of Lipton Tea (Camellia sinensis) on Normal Male Albino Rats
- Anti sense and sensibility: Renal and skin effects of (antisense) oligonucleotides
- β-Cell plasticity
- Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
- Benzimidazole: Journey from Single Targeting to Multitargeting Molecule
- Gut mechanisms linking intestinal sweet sensing to glycemic control
- Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
- Evaluation of antioxidant, hypoglycemic and hypolipidemic effects of the phytoconstituents of Cinnamomum tamala in rats
- OP8-4: Plasmalogens regulate macrophage polarization and protect against adipose tissue inflammation in high fat diet-fed mice
- PE-3: Artificial sweeteners content in sugar free products and public attitude of use in Muscat, Oman
- Silica-coated magnetic nanoparticles induce Glucose metabolic dysfunction in vitro via the generation of reactive oxygen species
- The relationship between peripheral Glucose utilisation and insulin sensitivity in the regulation of hepatic Glucose production: studies in normal and alloxan‐diabetic …
- Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model
- Nonlinear ODE mathematical analysis of the insulin-Glucose model in the presence of a condition in glycemia function H (G).
- A review: Medicinal plants and its impact on diabetes
- Antidiabetic, antioxidant and anti inflammatory properties of water and n-butanol soluble extracts from Saharian Anvillea radiata in high-fat-diet fed mice
- Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in Diabetes
- Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy
- Hypoglycemic and hypolipidemic effects of ethyl acetate leaf extract of Vitex simplicifolia in alloxan induced diabetic wister rats
- Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model Medhat M. Menshawy1 Abdel Razik H. Farrag 2, Sayed A. El …
- Role of Canagliflozin on function of CD34+ ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
- The Effect of Empagliflozin on Left Ventricular Mass and Myocardial Extracellular Volume in Patients with Type 2 Diabetes and Cardiovascular Disease
- Cress seed (lepidium sativum) role in the healthy processed spread cheese and its anti-diabetic activity
- Possible ways to improve postprandial Glucose control in type 1 diabetes
- New therapeutic agents for glycemic control in diabetes mellitus
- Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
- Role of some Egyptian medicinal plants against liver and kidney toxicity induced by cadmium chloride
- A new analytical method for determination of ledipasvir and sofosbuvir in pharmaceutical formulations by HPLC method
- Evaluation of medicinal plants used to diabetes treatment
- Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a …
- Skeletal muscle basal AMP-activated protein kinase activity is chronically elevated in alloxan-diabetic dogs: impact of exercise
- HERBAL INTERVENTIONS IN MANAGING DIABETES MELLITUS: A REVIEW
- Options for empagliflozin in combination therapy in type 2 diabetes mellitus
- Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial
- LEELA MADHURI POLA1
- The effects of plant-derived oleanolic acid on kidney function in male Sprague-Dawley rats and, in cell lines of the kidney and liver.
- Novel research strategies of benzimidazole derivatives: a review
- Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
- Type 2 diabetes mellitus and the elderly: an update on drugs used to treat glycaemia
- Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
- Natural Products Derived from the Mediterranean Diet with Antidiabetic Activity: from Insulin Mimetic Hypoglycemic to Nutriepigenetic Modulator Compounds
- Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
- Prevailing hyperglycemia is critical in the regulation of Glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs
- Factors influencing seed germination of the pastoral plant Retama raetam subsp. bovei (Fabaceae): interactive effects of fruit morphology, salinity, and osmotic stress
- on Pharmacometrics 2014 (ACoP5)
- Polyphenols of apples and their potential health benefits
- Endothelial Dysfunction in Diabetes: An Update on Mechanisms and Therapeutic Targets
- Studies on kidney pathophysiological analyses in SDT fatty rat, a novel obese diabetic model
- 19 Interview| Prof. dr. U. Beuers
- Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study.
- Evaluation of the stability of exenatide in aqueous solutions
- Clinical Trial Number NCT02635386
- Medicinal plants used for the treatment of diabetes and its long-term complications
- Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent …
- Fruit and vegetable waste management: Conventional and emerging approaches
- Diabetes mellitus and cardiovascular disease in the elderly
- CONTINUOUS Glucose MONITORING 1-OR
- NURDIANA BINTI SAMSULRIZAL
- The in vitro and in vivo anti-oxidative and anti-diabetic effects of some African medicinal plants and the identification of the bioactive compounds.
- In-depth Studies of the Antioxidant Profile of Aegle marmelos and Its Impact on Healthy and Type II Diabetes Mellitus Subjects
- Mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Effective diet against o minous octet
- Investigation of CPR knowledge dependence on driving experience and participation in first aid training
- The development and health of premature infants born before the 30th pregnancy week at the age of six
- Evaluation of mechanical power caused by different mechanical lung ventilation methods
- Neurological complications of pandemic A (H1N1) 2009PDM, post-pandemic (H1N1) V, and seasonal influenza A
- INSULIN TREATMENT IN TYPE 2 DIABETES
- General anesthesia from patients perspective: what myths are most common?
- Roots/Health Benefits of Apples
